PET and MRI Brain Imaging of Bipolar Disorder

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The primary aims of this study are to:

1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE).
2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT.
3. Assess the effect of lithium treatment of bipolar disorder on 5-HT1A BP.
4. Assess the effect of lamotrigine treatment of bipolar disorder on 5-HTT and 5-HT1A BP.
5. Assess the effect of lithium treatment of unipolar depression on 5-HTT BP.

Condition or disease	Intervention/treatment	Phase
Bipolar Disorder; Bipolar Depression; Unipolar Depression	Drug: Lithium; Drug: Lamotrigine	Not Applicable

Detailed Description:

PET and MRI imaging will be used to investigate the aims described above in patients who have bipolar disorder or unipolar depression and are currently experiencing a depressive episode. Both healthy controls and depressed participants with bipolar disorder or unipolar depression will be recruited. Patients who are on medication before enrolling in the study will have a three week washout. At baseline, healthy controls and patients will have an MRI consisting of both structural and functional sequences. Psychological measures will also be obtained at baseline. Within one week of the MRI, both patients and healthy controls will have one CUMI and one DASB PET scan.

Following the baseline PET scans, patient participants will begin medication treatment with either lithium or lamotrigine, based on the clinical judgement of the treating psychiatrist. Psychological measures will be obtained every 2 weeks. After 6 weeks of medication treatment at a therapeutic dose, patients will be assessed for remission (defined as a 50% decrease in the HDRS score from baseline). If this criteria is met, patient participants will then have follow-up PET scans (one CUMI and one DASB). If this criteria is not met, the patient will be switched to the other medication under study and will be reevaluated after an additional 4 weeks of medication treatment. Patients who still do not demonstrate a 50% decrease in their HDRS will be considered non-responders and will have repeat CUMI and DASB scans.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	76 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging
Study Start Date :	August 2012
Estimated Primary Completion Date :	May 2017

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Lithium; Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode	Drug: Lithium; Other Name: lithium carbonate
Lamotrigine; Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.	Drug: Lamotrigine; Other Name: Lamictal

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Hamilton Depression Rating Scale [ Time Frame: 6 weeks ]
   Patients will have a Hamilton Depression Rating Scale (HDRS) score obtained at baseline; participants must have an HDRS score of at least 15 to be eligible. After 6 weeks of medication treatment, the HDRS score will be reevaluated. Participants who have a 50% or greater decrease in their HDRS score will be considered responders and will proceed to the repeat PET scans.

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

PATIENTS

BIPOLAR

Inclusion Criteria:

• Bipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form—see Oquendo et al., 2003) for 4 weeks or more.
• Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.
• Age range 18-65 years.
• Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.
• Willing to travel for PET scanning

Exclusion Criteria:

• Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence <6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.
• A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).
• Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count < 80,000.
• Lacks capacity to consent.
• Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.
• Electroconvulsive therapy (ECT) within the past 6 months.
• Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.
• Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
• Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
• A neurological disease or loss of consciousness for more than a few minutes
• Medicinal Patch (participants will be asked to remove before MRI)
• Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study
• A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose >= 900 mgs) for at least 4 weeks.
• Patient is unlikely to be able to tolerate medication washout
• Claustrophobia
• Blood donation within 8 weeks of the start of the study.
• History of bleeding disorder or are currently taking anticoagulants.

UNIPOLAR

Inclusion:

• Unipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form—see Oquendo et al., 2003) for 4 weeks or more.
• Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.
• Age range 18-65 years.
• Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.
• Willing to travel for PET scanning

Exclusion:

• Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence <6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.
• A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).
• Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count < 80,000.
• Lacks capacity to consent.
• Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.
• Electroconvulsive therapy (ECT) within the past 6 months.
• Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.
• Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
• Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
• A neurological disease or loss of consciousness for more than a few minutes
• Medicinal Patch (participants will be asked to remove before MRI)
• Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study
• A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose >= 900 mgs) for at least 4 weeks.
• Patient is unlikely to be able to tolerate medication washout
• Claustrophobia
• Blood donation within 8 weeks of the start of the study.
• History of bleeding disorder or are currently taking anticoagulants.
• Past unsuccessful treatment of Lithium of adequate dose and duration.

HEALTHY CONTROLS

Inclusion:

• No lifetime history of Axis I disorders
• Age range 18-65 years.
• Willing to travel for PET scanning.

Exclusion:

• Past or present alcohol/substance abuse or dependence; IV drug use or ecstasy use more than two times.
• A first-degree relative with history of major depression, schizophrenia, schizoaffective disorder, or suicide attempt; two or more first degree relatives with a history of substance dependence.
• Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss, and the following lab parameters: platelet count < 80,000
• Lacks capacity to consent
• Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months
• Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
• Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
• A neurological disease or loss of consciousness for more than a few minutes
• Medicinal Patch (participants will be asked to remove before MRI)
• Subjects on drugs or medication that affect the serotonin system
• Claustrophobia
• Blood donation within 8 weeks of the start of the study.
• History of bleeding disorder or are currently taking anticoagulants.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Meghan Leonhardt, MA	631 638 1544	Meghan.Leonhardt@stonybrookmedicine.edu

Locations

United States, New York
Stony Brook University	Recruiting
Stony Brook, New York, United States, 11794
Principal Investigator: Ramin Parsey, MD, PhD

Sponsors and Collaborators

Stony Brook University

National Institute of Mental Health (NIMH)

The Dana Foundation

Investigators

Principal Investigator:	Ramin Parsey, MD, PhD	Stony Brook University

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Stony Brook University
ClinicalTrials.gov Identifier:	NCT01880957 History of Changes
Other Study ID Numbers:	2012-1826-F; 7R01MH090276-03 ( U.S. NIH Grant/Contract )
First Posted:	June 19, 2013
Last Update Posted:	July 19, 2016
Last Verified:	July 2016

Keywords provided by Stony Brook University:

bipolar disorder; bipolar depression; serotonin transporter; serotonin receptors	binding potential; brain imaging; unipolar depression

Additional relevant MeSH terms:

Disease; Depressive Disorder; Bipolar Disorder; Mood Disorders; Mental Disorders; Bipolar and Related Disorders; Depression; Pathologic Processes; Behavioral Symptoms; Lithium Carbonate; Lamotrigine; Anticonvulsants; Serotonin; Antidepressive Agents; Psychotropic Drugs

Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antimanic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Calcium Channel Blockers; Membrane Transport Modulators; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Neurotransmitter Agents; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Serotonin Receptor Agonists; Serotonin Agents